Tonghua Dongbao Secures Marketing Authorization in Uzbekistan for Human Insulin Injection
By Thomas Yuan

TONGHUA — Tonghua Dongbao announced on March 20 that it has received marketing authorization from the Ministry of Health of the Republic of Uzbekistan for its Protamine Human Insulin Mixed Injection (30R), marking a strategic advancement in the company’s international expansion across Belt and Road markets.

The approved product, a 10ml injectable insulin formulation, combines 30% soluble human insulin with 70% protamine zinc insulin suspension, offering both rapid postprandial glucose control and basal insulin support. It is indicated for the treatment of both type 1 and type 2 diabetes, conditions that continue to see rising global prevalence and impose significant health and economic burdens.

The product's registration number is DV/X 10875/03/25, and Tonghua Dongbao is listed as the marketing authorization holder.

Expanding Access to Chronic Disease Therapies

Tonghua Dongbao emphasized that the authorization strengthens its biopharmaceutical product line in international markets and enhances its brand visibility abroad. Uzbekistan, with its large population and growing demand for chronic disease management solutions, presents a high-potential market for diabetes treatments and essential health products.

The approval also reflects China's growing role in global medical supply chains and insulin-based drug exports, offering more affordable alternatives in regions where access to quality diabetes care remains limited.

Financial Outlook and Market Strategy

Despite reporting a net loss of ¥66.37 million on ¥1.448 billion in revenue during the first three quarters of 2024, Tonghua Dongbao’s overseas regulatory progress signals renewed momentum. By targeting high-need therapeutic areas such as metabolic diseases and expanding in emerging markets, the company aims to position itself as a competitive player in the international pharmaceutical landscape.

The company’s growing portfolio of recombinant insulin products, alongside investments in R&D and regulatory strategy, aligns with long-term goals to scale its medical technology exports, improve global diabetes management, and drive sustainable growth through international health partnerships.

https://finance.eastmoney.com/a/202503203351266354.html